



For Health Professionals Who Care For Cancer Patients

Inside This Issue:

- **Editor's Choice** – New Programs: Chemoradiation with Carboplatin and Paclitaxel for Lung Cancer
- **Cancer Drug Manual** – New: Nivolumab Revised: Capecitabine, Fluorouracil
- **Medication Safety** – BCCA Medication Safety Subcommittee
- **Benefit Drug List** – New: Carboplatin, Clodronate, Cyclophosphamide, Imatinib, Paclitaxel, Topotecan
- **List of New and Revised Protocols, Provincial Pre-Printed Orders and Patient Handouts** – New: LULACATRT Revised: BRAVCLOD, GOOVTOP, LKCMLI, LUSCTOP, SAAJGI, SAAVGI, SAAVGIDD, SAAVTC
- **Erratum**
- **Website Resources and Contact Information**

EDITOR'S CHOICE

NEW PROGRAMS

The Provincial Systemic Therapy Program has approved the following program effective 1 September 2015:

Lung:

Carboplatin and Paclitaxel with Radiotherapy for Locally Advanced Non-Small Cell Lung Cancer (LULACATRT)

– A new chemoradiation regimen for patients with locally advanced non-small cell lung cancer (NSCLC) is now available. It is an alternative to the existing cisplatin and etoposide protocols (LULAPERT, LULAPE2RT). This new regimen involves low dose weekly carboplatin and paclitaxel concurrent with radiation therapy, followed by consolidation with two cycles of 3-weekly regular doses of carboplatin and paclitaxel [Belani CP, et al. *J Clin Oncol* 2005;23:5883, Satana-Davila R, et al. *J Clin Oncol* 2015;33:567.]. This regimen offers an alternative to patients who may not tolerate the cisplatin-based regimens, such as patients who are elderly and frail or with impaired renal function.

CANCER DRUG MANUAL

NEW MONOGRAPH

Nivolumab Interim Monograph has been developed. Nivolumab is a humanized monoclonal antibody that functions as an immune checkpoint inhibitor. It inhibits the interaction between the programmed death receptor-1 (PD-1) and ligands (PD-L1, PD-L2), thereby disrupting the negative signalling and leading

CANCER DRUG MANUAL

to restored T-cell antitumour function. Nivolumab is associated with immune-mediated adverse events, including pneumonitis, colitis, hepatitis, nephritis, hypothyroidism and hyperthyroidism. Management of these toxicities may include stopping nivolumab and/or initiating corticosteroids and other symptomatic treatment.

Nivolumab is available only through Health Canada Special Access Programme and the BCCA Compassionate Access Program. The usual dosing is 3 mg/kg administered intravenously every two weeks, although other regimens have been used in clinical trial settings. For the purpose of safe handling it is considered a hazardous drug.

REVISED MONOGRAPHS

Capecitabine and **Fluorouracil** interaction with warfarin has been updated with more details on the clinical effects and mechanism of the interaction.

MEDICATION SAFETY

BCCA MEDICATION SAFETY SUBCOMMITTEE

Who are we and what do we do?

- An interprofessional cross-program provincial committee formed in 2014.
- Committed to reducing the occurrence of medication adverse events by providing recommendations, action items, and communication regarding safe medication practices.
- We strive to continually improve the safety and quality of care to patients in BCCA, using an interdisciplinary focus.

To whom do we report?

- BCCA Provincial Systemic Therapy Program and the Quality Council

Ongoing activities of BCCA Medication Safety Subcommittee

- Develop strategies to address the impact of interruptions on safety during all aspects of medication management process, from prescription to administration.
- Review new Accreditation Canada Medication Management Required Organizational Practices (ROPs) and plan for necessary changes e.g. High Alert Medication Policy.
- Review elements of protocol/pre-printed order naming and design to reduce risk of errors, e.g. piloted colour coding of breast protocol codes on website ([Nov 2014 Systemic Therapy Update](#))
- Work in collaboration with Quality and Safety team to review medication related events and develop strategies for error prevention.
- Identify and determine recommendations/strategies to manage medication safety concerns for DUAL modality patients.
- Use medication safety subcommittee as a forum for members to share ideas and identify medication safety opportunities on a continuous basis.

We need you

- We are continually striving to improve the medication management system and we need your input. Connect with a medication safety subcommittee member at your BCCA regional centre if you have

MEDICATION SAFETY

any medication safety ideas, concerns or learning to share.

Current membership

Co-chairs

Karen Janes (Nursing Professional Practice Leader)
Tonya Ng (Provincial Medication Safety Coordinator)

Pharmacy

Crystal Maric (Professional Practice Leader -VC)
Rose Maleschuk (VIC)
Linda Hamata (VC)
Juliana Man (VC alternate)
Amber Tew (CSI)

Nursing

Janice Dirksen, Clinical Nurse Coordinator (VC Inpatient Unit)
Arlyn Heywood, Education Resource Nurse (VC Inpatient Unit)
Shereen Looi, Assessment Module Leader (VC)
Yvonne Miller, Clinical Nurse Leader (FVC)
Mary Beth Rawling, Clinical Nurse Coordinator (CN)
Theresa Zapach, Education Resource Nurse (VIC)

Unit Clerks

Lynne Williams (FVC)
Steve Lundie (VC alternate)
Elisabeth Tanner (VC alternate)

Quality and Safety/Risk Management

Sue Fuller-Blamey (Corporate Director, Quality & Safety)
Tracy Lust (Quality, Safety and Accreditation Leader)

Medical Oncologists

Barbara Czerkawski (CSI)
Abdul Al-Tourah (FVC)

Regional Director/Manager of Clinical Services

Alison Pow (CN)

BENEFIT DRUG LIST

NEW PROGRAM

The following program has been added to the [Benefit Drug List](#) effective 1 September 2015:

Protocol Title	Protocol Code	Benefit Status
Treatment of locally advanced non-small cell lung cancer using <i>carboplatin</i> and <i>paclitaxel</i> with radiation therapy	LULACATRT	Class I

REVISED PROGRAMS

The following programs have been revised on the [Benefit Drug List](#) from Class II to Class I status, effective 1 September 2015:

Indications	Protocol Code
Therapy of bone metastases in breast cancer using oral <i>clodronate</i>	BRAVCLOD
Treatment of relapsed/progressing epithelial ovarian, primary peritoneal, or fallopian tube carcinoma using <i>topotecan</i>	GOOVTOP

BENEFIT DRUG LIST

Treatment of chronic myeloid leukemia and Ph+ acute lymphoblastic leukemia using <i>imatinib</i>	LKCMLI
Second-line treatment of recurrent small cell lung cancer with <i>topotecan</i>	LUSCTOP
Treatment of pediatric sarcoma using <i>topotecan</i>	PENOS
Treatment of intermediate-risk (COG ANBL0532) and high risk (COG ANBL0531) pediatric neuroblastoma using <i>topotecan</i>	PENOS
Treatment of pediatric Philadelphia chromosome positive acute lymphoblastic leukemia using imatinib	PENOS
Adjuvant treatment of C-Kit Positive high risk gastrointestinal stromal cell tumours using <i>imatinib</i>	SAAJGI
Treatment of advanced C-Kit Positive and C-Kit negative gastrointestinal stromal cell tumours using <i>imatinib</i>	SAAVGI
Treatment of advanced C-Kit Positive gastrointestinal stromal cell tumours using 800 mg dosing of <i>imatinib</i>	SAAVGIDD
Treatment of recurrent/refractory neuroblastoma, Ewing's sarcoma, osteogenic sarcoma or rhabdomyosarcoma with <i>topotecan/cyclophosphamide</i>	SAAVTC

LIST OF NEW AND REVISED PROTOCOLS, PRE-PRINTED ORDERS AND PATIENT HANDOUTS

BC Cancer Agency Protocol Summaries, Provincial Pre-Printed Orders (PPPOs) and Patient Handouts are revised periodically. New, revised or deleted protocols, PPPOs and patient handouts for this month are listed below. Protocol codes for treatments requiring BCCA Compassionate Access Program approval are prefixed with the letter "U".

NEW PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Protocol Title
LULACATRT	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	Treatment of Locally Advanced Non-Small Cell Lung Cancer Using Alternative Dosing of CISplatin and Etoposide with Radiation Therapy

REVISED PROTOCOLS, PPPOs AND PATIENT HANDOUTS (AFFECTED DOCUMENTS ARE CHECKED):

CODE	Protocol	PPPO	Patient Handout	Changes	Protocol Title
BRAVCLOD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Class II requirement deleted</i>	Therapy of Bone Metastases in Breast Cancer using Oral Clodronate
GOOVTOP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Class II requirement deleted</i>	Treatment of Relapsed/Progressing Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma Using Topotecan
LKCMLI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Class II requirement deleted</i>	Treatment of Chronic Myeloid Leukemia and Ph+ Acute Lymphoblastic Leukemia Using Imatinib
LUSCTOP	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Class II requirement deleted</i>	Second-line Treatment of Recurrent Small Cell Lung Cancer with Topotecan
SAAJGI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Class II requirement deleted</i>	Adjuvant Treatment of C-Kit Positive High Risk Gastrointestinal Stromal Cell Tumours Using Imatinib
SAAVGI	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Class II requirement deleted</i>	Treatment of Advanced C-Kit Positive and C-Kit Negative Gastrointestinal Stromal Cell Tumours (GISTs) Using Imatinib
SAAVGIDD	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Class II requirement deleted</i>	Treatment of Advanced c-Kit Positive Gastrointestinal Stromal Cell Tumours Using 800 mg Dosing of Imatinib
SAAVTC	<input checked="" type="checkbox"/>	<input checked="" type="checkbox"/>	<input type="checkbox"/>	<i>Class II requirement deleted</i>	Treatment of Recurrent/Refractory Neuroblastoma, Ewing's Sarcoma, Osteogenic Sarcoma or Rhabdomyosarcoma with Topotecan/Cyclophosphamide

ERRATUM

In the summary of the new chemoradiation protocol for lung cancer in the August 2015 issue of the Systemic Therapy Update, it should read “*This alternative regimen has a **lower** total cumulative cisplatin dose (200 mg/m²) given over two cycles compared to the existing LULAPERT protocol (300 mg/m²) over two cycles concurrent with radiation and two cycles as consolidation.*”

WEBSITE RESOURCES AND CONTACT INFORMATION

WEBSITE RESOURCES	www.bccancer.bc.ca
Systemic Therapy Update	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy/systemic-therapy-update
Reimbursement & Forms: Benefit Drug List, Class II, Compassionate Access Program	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
Cancer Drug Manual	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-drug-manual
Cancer Management Guidelines	www.bccancer.bc.ca/health-professionals/professional-resources/cancer-management-guidelines
Cancer Chemotherapy Protocols, Pre-printed Orders, Protocol Patient Handouts	www.bccancer.bc.ca/health-professionals/professional-resources/chemotherapy-protocols
Systemic Therapy Program Policies	www.bccancer.bc.ca/health-professionals/professional-resources/systemic-therapy
CON Pharmacy Educators	www.bccancer.bc.ca/health-professionals/professional-resources/pharmacy

CONTACT INFORMATION	PHONE	FAX	EMAIL
Systemic Therapy Update Editor			bulletin@bccancer.bc.ca
Provincial Systemic Therapy Program	604-877-6000 x 672247		mclin@bccancer.bc.ca
To update the contact information of any CON sites, please contact:			bulletin@bccancer.bc.ca
Oncology Drug Information	604.877.6275		druginfo@bccancer.bc.ca
Education Resource Nurse	604.877.6000 x 672638		nursinged@bccancer.bc.ca
Library/Cancer Information	604.675.8003 Toll Free 888.675.8001 x 8003		requests@bccancer.bc.ca
Pharmacy Professional Practice	604.877.6000 x 672247		mclin@bccancer.bc.ca
Nursing Professional Practice	604.877.6000 x 672623		ilundie@bccancer.bc.ca
OSCAR	888.355.0355	604.708.2051	oscar@bccancer.bc.ca
Compassionate Access Program (CAP)	604.877.6277	604.708.2026	cap_bcca@bccancer.bc.ca
Pharmacy Chemotherapy Certification	250.712.3900 x 686741		rxchemocert@bccancer.bc.ca
BCCA-Abbotsford Centre	604.851.4710 Toll Free 877.547.3777		
BCCA-Centre for the North	250.645.7300 Toll Free 888.775.7300		
BCCA-Fraser Valley Centre	604.930.2098 Toll Free 800.523.2885		
BCCA-Sindi Ahluwalia Hawkins Centre for the Southern Interior	250.712.3900 Toll Free 888.563.7773		
BCCA-Vancouver Centre	604.877.6000 Toll Free 800.663.3333		
BCCA-Vancouver Island Centre	250.519.5500 Toll Free 800.670.3322		

EDITORIAL REVIEW BOARD

Mário de Lemos, PharmD, MSc (Oncol) (Acting Editor)
 Victoria Kletas, MSc (Clin Pharm)
 Caroline Lohrisch, MD
 Robert Crisp, BScPT, MBA

Beth Morrison, MLS
 Ava Hatcher, RN, BN, CON(c)
 Rob Watt, BSc (Pharm)